American Society of Hematology

SHERPA: Blue

People

  1. Thompson
    Thompson
  2. Zelenetz
    Zelenetz
  3. Geyer
    Geyer
  4. Park
    Park
  5. Abdel-Wahab
    Abdel-Wahab
  6. Derkach
    Derkach
  7. Palomba
    Palomba
  8. Goldberg
    Goldberg
  9. Islam
    Islam
  10. Falchi
    Falchi

Groups

  1. Department of Medicine (66)
  2. Hematologic Malignancies, Division of (66)
  3. Hematology-Oncology Fellows (66)
  4. Center for Hematologic Malignancies (48)
  5. Adult Leukemia (47)
  6. GME, Medicine (21)
  7. Graduate Medical Education (21)
  8. Lymphoma (19)
  9. Weinberg Fellows (11)
  10. Biostatistics Service (9)
Search Within
  1. "Lindsey Roeker"
Formats
  1. Meeting Abstract (53)
  2. Journal Article (10)
  3. Research Letter (2)
  4. Editorial (1)
Groups
  1. Department of Medicine (66)
  2. Hematologic Malignancies, Division of (66)
  3. Hematology-Oncology Fellows (66)
  4. Center for Hematologic Malignancies (48)
  5. Adult Leukemia (47)
  6. GME, Medicine (21)

More Groups

People
  1. Lindsey Roeker (66)
  2. Anthony Mato (40)
  3. Andrew Zelenetz (19)
  4. Meghan Thompson (19)
  5. Mark Geyer (9)
  6. Jae Park (7)

More People

Years
  1. 2024 (13)
  2. 2023 (12)
  3. 2022 (9)
  4. 2021 (11)
  5. 2020 (8)
  6. 2019 (9)

More Years

Publications
  1. Blood (58)
  2. Blood Advances (7)
  3. Hematology-American Society of Hematology Education Program (1)

Results (66)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: A medical chart review study
    Meeting Abstract

    Shadman, M.; Roeker, L.; Pinilla-Ibarz, J.; Srivastava, B.; Karve, S.; Krigsfeld, G. S.; Franceschini, E.; Saifan, C.; Karanth, S.; Goyal, R. K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase 1/2 studies of DZD8586, a non-covalent BBB penetrant LYN/BTK dual inhibitor, in BTK inhibitor resistant chronic lymphocytic Leukemia (CLL) and other B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Song, Y.; Zhou, K.; Jing, H.; Chong, G.; Wu, J.; Liu, W.; Li, Z.; Jiang, M.; Lan, M.; Ding, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A multi-center retrospective study on complex karyotype in patients with Richter transformation who received no chemoimmunotherapy for their CLL
    Meeting Abstract

    Miller, C.; Huang, Y.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; Danilov, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes of therapies following discontinuation of non-covalent Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and Richter transformation: Results from an international, multicenter study
    Meeting Abstract

    Thompson, M. C.; Bhat, S. A.; Jurczak, W.; Patel, K.; Shah, N. N.; Woyach, J. A.; Coombs, C. C.; Eyre, T. A.; Danecki, M.; Dlugosz-Danecka, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Mátrai, Z.; Sanna, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study
    Meeting Abstract

    Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax
    Journal Article

    Valtis, Y. K.; Nemirovsky, D.; Derkach, A.; Sharan, S.; Kabel, C.; Ortiz, R.; Thompson, M. C.; Roeker, L. E.; Geyer, M. B.
    Blood Advances (2024)

    Fulltext@MSK | Save